GeneDx CEO and CFO Named in Securities Class Action Over $33.42 Per-Share Losses
WGS has more than doubled off its 52-week low of $32.21.
Summary
A new securities class action filing names GeneDx CEO Katherine Stueland and CFO Kevin Feeley as individual defendants, alleging they misled investors about the Fabric Genomics integration and revenue guidance. The suit covers purchases between April 16, 2025 and May 4, 2026, and claims the executives knew Fabric was underperforming while certifying financial disclosures. The stock fell 49.2% after the company disclosed a $31.2 million impairment charge and cut full-year revenue guidance by $65 million. The lead plaintiff deadline is August 3, 2026. This follows a June 29 investigation announcement by Hagens Berman, but adds specific individual liability claims and a court-set deadline.
At the time of this announcement, WGS was trading at $65.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $32.21 to $170.87. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.